

U.S. National Library of Medicine National Center for Biotechnology Information **NLM Citation:** Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Alemtuzumab. [Updated 2019 Feb 28]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



# Alemtuzumab

Revised: February 28, 2019.

CASRN: 216503-57-0

## **Drug Levels and Effects**

## Summary of Use during Lactation

No information is available on the clinical use of alemtuzumab during breastfeeding. Because alemtuzumab is a large protein molecule with a molecular weight of 145,454, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, alemtuzumab should be used with caution or avoided during breastfeeding, especially while nursing a newborn or preterm infant.[1][2][3]

### **Drug Levels**

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

### **Effects in Breastfed Infants**

Relevant published information was not found as of the revision date.

### **Effects on Lactation and Breastmilk**

Relevant published information was not found as of the revision date.

### **Alternate Drugs to Consider**

(Multiple Sclerosis) Glatiramer, Immune Globulin, Interferon Beta

### References

- 1. Bove R, Alwan S, Friedman JM et al. Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. Obstet Gynecol. 2014;124:1157-68. PubMed PMID: 25415167.
- 2. Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler. 2013;19:835-43. PubMed PMID: 23319073.

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site .

3. Almas S, Vance J, Baker T et al. Management of multiple sclerosis in the breastfeeding mother. Mult Scler Int. 2016;2016:6527458.9 PubMed PMID: 2696657.

## **Substance Identification**

#### **Substance Name**

Alemtuzumab

#### **CAS Registry Number**

216503-57-0

#### **Drug Class**

Breast Feeding Lactation

Antineoplastic Agents

Antibodies, Monoclonal, Humanized

Immunosuppressive Agents